Skip to main content
Full access
Letter
Published Online: 1 May 1999

The Schizophrenia Algorithm

To the Editor: The authors of the article describing the development and implementation of the schizophrenia algorithm (1) in the January issue are to be congratulated on a useful and readable presentation. However, I have some questions about some of the stages of the algorithm. For stage 1, where there is "no history of typical antipsychotic failure," the algorithm indicates a switch to "olanzapine or quetiapine or risperidone." This course seems a bit uncompromising. What about a patient with chronic schizophrenia who has done well on small doses of typical antipsychotics, is not on anticholinergics, and manifests no adverse side effects? Should such a person be switched?
In stage 6, the use of "atypical plus typical, or combination of atypicals, or typical or atypical plus ECT" is problematic in the sense that it is far too inclusive. Patients who respond to combinations of medications should not be lumped together with patients who require electroconvulsive therapy, either alone or in combination with medications. It seems to me stage 6 should be subdivided into several categories.
Also, I would question why in stage 5 clozapine is listed as an algorithmic option before the choice of using a combination of medications as represented in stage 6. It seems to me that a combination of two antipsychotics, either typical or atypical, in any permutation is less hazardous, less expensive, and less inconvenient to the patient than clozapine, which requires biweekly, weekly, and sometimes twice-weekly white blood cell counts. Why not offer combination therapy before clozapine therapy unless there is an a priori theoretical bias against combinations? I thought the days of regarding all forms of polypharmacy as intrinsically evil were over. Possibly this sequence exists because stage 6 was not subdivided into non-ECT and ECT categories.
It is in the middle stages that the algorithm is most useful, and I find myself referring to it in my own progress notes, written in California as if the eyes of Texas were upon me. I believe this to be the highest form of compliment, so congratulations again to the authors.

Footnote

Dr. Fleishman is in private practice in San Francisco.

Information & Authors

Information

Published In

Go to Psychiatric Services
Go to Psychiatric Services
Psychiatric Services
Pages: 703a - 703
PubMed: 10332913

History

Published online: 1 May 1999
Published in print: May 1999

Authors

Affiliations

Martin Fleishman, M.D., Ph.D.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Psychiatric Services

PPV Articles - Psychiatric Services

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share